Tiamulin (Thiamutilin): Pleuromutilin Antibiotic for Veterinary Infectious Disease Control

Executive Summary: Tiamulin (Thiamutilin, BA1083) is a semi-synthetic pleuromutilin antibiotic licensed primarily for veterinary use in pigs and poultry, with well-documented efficacy against Mycoplasma gallisepticum and other respiratory pathogens (Xiao et al., 2016). Its antibacterial action derives from selective binding to the peptidyl transferase center of the 50S ribosomal subunit, disrupting protein synthesis at 23S rRNA nucleotides A2058, A2059, G2505, and U2506. Tiamulin exhibits anti-inflammatory properties through modulation of TNF-α-driven NF-κB, MAPK, and JAK/STAT3 pathways. Its pharmacokinetics in poultry demonstrate required serum concentrations above 8.8 μg/mL and an AUC24h/MIC ≥ 382.58 h to reduce bacterial load. APExBIO supplies Tiamulin (Thiamutilin) BA1083 for research and veterinary applications (product page).

Biological Rationale

Tiamulin (CAS No. 55297-95-5) is a pleuromutilin derivative synthesized for enhanced selectivity and spectrum in veterinary applications. Its primary indication is the control and treatment of infectious diseases in pigs and poultry, notably chronic respiratory disease caused by Mycoplasma gallisepticum (Xiao et al., 2016). The compound's mechanism and spectrum make it valuable for both disease control and as a research tool for inflammatory pathway modulation. Tiamulin is also being evaluated for translational anti-inflammatory applications, including topical formulations for psoriasis-like dermatitis (APExBIO).

Mechanism of Action of Tiamulin (Thiamutilin)

Tiamulin acts as a bacterial protein synthesis inhibitor. It binds specifically to the peptidyl transferase center (PTC) of the 50S ribosomal subunit. The interaction occurs at 23S rRNA nucleotides A2058, A2059, G2505, and U2506, blocking peptide bond formation and thus inhibiting protein elongation (Xiao et al., 2016). This mode of action underpins its high potency against Gram-positive bacteria and mycoplasmas.

In addition to its antibacterial activity, Tiamulin modulates inflammation by inhibiting TNF-α-mediated signaling. It exerts effects on the NF-κB, MAPK, and JAK/STAT3 pathways, resulting in dampened pro-inflammatory cytokine production (Tiamulin: Pleuromutilin Antibiotic for Veterinary Use). This dual mechanism distinguishes Tiamulin among veterinary antibiotics.

Evidence & Benchmarks

• Tiamulin demonstrates an in vitro MIC of 0.03 μg/mL against M. gallisepticum strain S6 (DOI: 10.3389/fvets.2016.00075).
• Effective in vivo pathogen load reduction is achieved with an AUC24h/MIC ≥ 382.58 h and steady-state serum concentrations above 8.8 μg/mL in chickens (Xiao et al., 2016).
• Recommended treatment regimen for M. gallisepticum infection in poultry: 45 mg/kg/day intramuscularly for three days (DOI: 10.3389/fvets.2016.00075).
• Tiamulin inhibits TNF-α-induced inflammatory responses via the NF-κB and MAPK pathways, verified in cellular models (Tiamulin: Pleuromutilin Antibiotic for Veterinary Use).
• Veterinary maximum residue limits are 100 μg/kg in muscle and 500 μg/kg in liver tissues (APExBIO product page).

Applications, Limits & Misconceptions

Tiamulin is approved for veterinary infectious disease control in pigs and poultry, targeting pathogens such as Mycoplasma gallisepticum, Actinobacillus pleuropneumoniae, and Gram-positive bacteria. Its use as an anti-inflammatory agent is under investigation, including topical treatment for psoriasis-like dermatitis. Typical in vitro concentrations range from 10 to 200 μM, while in vivo doses span 5–80 mg/kg (chickens) and 10–20 mg/kg (pigs), with oral dosing at 20 mg/kg.

For advanced mechanistic and translational insights, see Tiamulin: Precision Mechanisms and Next-Gen Applications, which explores structural ribosome interactions and resistance. This article updates that content by detailing residue-level ribosomal binding and current PK/PD benchmarks.

For expanded pharmacology and metabolism, Tiamulin: Advanced Pharmacology and Metabolism offers a species-specific metabolic perspective, while this article focuses on standardized efficacy and dosing parameters.

Common Pitfalls or Misconceptions

• Tiamulin is ineffective against Gram-negative bacteria outside its approved spectrum.
• It should not be used in animals intended for human consumption within the withdrawal period, due to residue limits.
• Long-term storage of Tiamulin solutions is not recommended; use freshly prepared solutions for reproducibility.
• Topical anti-inflammatory use is investigational and not currently approved for human clinical therapy.
• Resistance can develop with improper dosing or prolonged use; always adhere to PK/PD-guided regimens.

Workflow Integration & Parameters

Tiamulin (Thiamutilin) BA1083 is supplied as an oil with a molecular weight of 493.74 and formula C₂₈H₄₇NO₄S (APExBIO). It is soluble in DMSO (≥50.5 mg/mL) and ethanol (≥59.9 mg/mL), but insoluble in water. Store at -20°C. Recommended in vitro working concentrations: 10–200 μM. For animal models: intramuscular 5–80 mg/kg (chickens), 10–20 mg/kg (pigs), or oral 20 mg/kg. Maintain serum concentrations >8.8 μg/mL for efficacy against M. gallisepticum.

For workflows targeting anti-inflammatory outcomes, select concentrations capable of modulating TNF-α/NF-κB and MAPK pathways in the relevant cell or tissue system. Do not exceed veterinary maximum residue limits in food-producing animals.

For further practical guidance and troubleshooting, consult Tiamulin: Dual-Action Veterinary Antibiotic, which provides actionable workflows and translational insights. This article clarifies current dosing standards and evidence benchmarks for BA1083.

Conclusion & Outlook

Tiamulin (Thiamutilin, BA1083) is a robust pleuromutilin antibiotic for veterinary infectious disease control, with dual antibacterial and anti-inflammatory properties substantiated by residue-level mechanistic and PK/PD data. Its role as a bacterial protein synthesis inhibitor (via 23S rRNA binding) is well-established in controlling M. gallisepticum and related pathogens (Xiao et al., 2016). Emerging anti-inflammatory research extends its potential utility. APExBIO provides Tiamulin (Thiamutilin) BA1083 as a validated reagent for both research and veterinary use (product page).